1-Methylindole-3-carboxaldehyde semicarbazone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-Methylindole-3-carboxaldehyde semicarbazone
• 英文别名: [(E)-(1-methylindol-3-yl)methylideneamino]urea
• 化学式: C₁₁H₁₂N₄O
• mdl: MFCD00810175
• 分子量: 216.242
• InChiKey: XCLVIUURVQDJLE-AWNIVKPZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  72.4
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Compositions and methods for inhibiting platelet activation and thrombosis
  申请人：Beth Israel Deaconess Medical Center

  公开号：US20040147540A1

  公开（公告）日：2004-07-29

  The invention provides methods and compositions for reducing platelet activation, platelet aggregation and thrombosis. The invention further provides compositions and methods for treating or preventing diseases or disorders in which the pathology of the disease or disorder involves one or more of platelet activation, platelet aggregation and thrombus formation. The invention additionally relates to the use of protein palmitoylation inhibitors for the reduction of platelet activation, platelet aggregation and thrombosis, as well as to the use of protein palmitoylation as a target for the identification of inhibitors of platelet activation, platelet aggregation and thrombosis.

  本发明提供了减少血小板活化、血小板聚集和血栓形成的方法和组合物。本发明进一步提供了用于治疗或预防疾病或失调的组合物和方法，其中疾病或失调的病理涉及血小板活化、血小板聚集和血栓形成中的一种或多种。本发明还涉及使用蛋白棕榈酰化抑制剂降低血小板活化、血小板聚集和血栓形成，以及使用蛋白棕榈酰化作为靶点鉴定血小板活化、血小板聚集和血栓形成抑制剂。
• COMPOSITIONS AND METHODS FOR INHIBITING PLATELET ACTIVATION AND THROMBOSIS
  申请人：Beth Israel Deaconess Medical Center

  公开号：EP1406621A2

  公开（公告）日：2004-04-14
• US7166612B2
  申请人：——

  公开号：US7166612B2

  公开（公告）日：2007-01-23
• [EN] COMPOSITIONS AND METHODS FOR INHIBITING PLATELET ACTIVATION AND THROMBOSIS<br/>[FR] COMPOSITIONS ET PROCEDES PROHIBANT L'ACTIVATION PLAQUETTAIRE ET LA THROMBOSE
  申请人：BETH ISRAEL HOSPITAL

  公开号：WO2003001968A2

  公开（公告）日：2003-01-09

  The invention provides methods and compositions for reducing platelet activation, platelet aggregation and thrombosis. The invention further provides compositions and methods for treating or preventing diseases or disorders in which the pathology of the disease or disorder involves one or more of platelet activation, platelet aggregation and thrombus formation.